US FDA places partial clinical hold on Gilead’s studies on Magrolimab for AML treatment
The FDA action follows the previously announced discontinuation of the Phase 3 ENHANCE study of magrolimab in higher-risk…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
higher-risk myelodysplastic syndromes
US FDA grants Breakthrough Therapy Designation for Takeda’s Pevonedistat
The investigational drug is for the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS)